8-K: Bioxytran Designates 49.5 Million Shares of Convertible Preferred Stock and Appoints New Director

Bioxytran, Inc. has designated 49.5 million shares of convertible preferred stock and appointed Dr. Radka Milanova to its Board of Directors, effective April 19, 2024.

Summary

• Bioxytran, Inc. has established 49.5 million shares of Convertible Preferred Stock, out of a total of 50 million authorized preferred shares.
• These preferred shares have enhanced voting rights, equivalent to ten votes per share on an as-converted basis.
• Company insiders, including officers and directors, can exchange their common stock for preferred stock at a ratio of 5 common shares for 1 preferred share.
• Each preferred share can be converted into 5 common shares, subject to adjustments for stock splits, dividends, and reorganizations.
• The company will not pay cash dividends on the preferred stock unless the board decides to do so, but preferred shareholders will receive equivalent dividends to common shareholders on an as-converted basis.
• Preferred stock ranks senior to common stock in terms of dividend payments and asset distribution during liquidation.
• Dr. Radka Milanova has been appointed to the Board of Directors, effective April 19, 2024, filling a vacancy.
• Dr. Milanova will receive $5,000 in common stock for each board or committee meeting attended, and may receive additional stock or stock options.

Sentiment

Score: 7

Explanation: The document outlines positive changes in the company's capital structure and board composition, suggesting a positive outlook. The appointment of a new director with significant experience is a positive development.

Positives

• The creation of convertible preferred stock provides flexibility for the company's capital structure.
• The enhanced voting rights of the preferred stock may provide more influence for certain shareholders.
• The appointment of Dr. Milanova brings significant pharmaceutical development and business expertise to the board.
• Dr. Milanova's experience includes successful IND and NDA applications, patents, and revenue generation.

Negatives

• The preferred stock does not guarantee cash dividends unless the board decides to declare them.
• The conversion of preferred stock to common stock could potentially dilute existing common shareholders.

Risks

• The conversion of preferred stock could increase the number of outstanding common shares, potentially diluting the value of existing shares.
• The company's ability to pay dividends on preferred stock is subject to the board's discretion.
• The company's future performance will depend on the effectiveness of the new board member and the management team.

Future Outlook

The company has established a framework for the conversion of preferred stock and the potential for future adjustments based on corporate actions. The appointment of Dr. Milanova is expected to contribute to the company's strategic direction and growth.

Management Comments

• The Board of Directors believes that Dr. Milanova's expertise and experience in practicing pharmaceutical development, her perspective, depth and background in business development and out-licensing, and her leadership experience in the field of biotechnology provide her with the qualifications and skills to serve on our Board of Directors.

Industry Context

The creation of convertible preferred stock is a common financing strategy for biotechnology companies, providing flexibility in capital structure and potentially attracting investors. The appointment of a seasoned executive like Dr. Milanova is also typical for companies seeking to advance their drug development programs and commercialization efforts.

Comparison to Industry Standards

• The use of convertible preferred stock is a common practice among biotech companies, similar to companies like Amgen and Gilead Sciences, which have used various forms of preferred stock to raise capital and manage their capital structure.
• The 5:1 exchange ratio and 1:5 conversion ratio are within the typical range for such instruments, although the specific terms are tailored to Bioxytran's needs.
• The appointment of a director with extensive experience in drug development and commercialization is a common practice in the biotech industry, similar to companies like Regeneron and Vertex Pharmaceuticals, which often recruit board members with specific expertise.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution if preferred stock is converted to common stock.
• Employees may benefit from the company's growth and strategic direction.
• Customers may benefit from the company's enhanced drug development capabilities.
• Creditors may be impacted by changes in the company's capital structure.

Next Steps

• The company will need to manage the conversion of preferred stock and ensure compliance with all relevant regulations.
• The company will need to integrate Dr. Milanova into the board and leverage her expertise.
• The company will need to monitor the impact of the preferred stock on the company's capital structure and share price.

Key Dates

Keywords

Convertible Preferred Stock, Preferred Stock, Board of Directors, Radka Milanova, Stock Conversion, Voting Rights, Bioxytran, Corporate Governance